Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Casesneurology-neurodisability-and-neuromuscular

Paeds Cases · neurology-neurodisability-and-neuromuscular

Duchenne and Becker muscular dystrophy: Case

Clinical case of a boy with Duchenne muscular dystrophy presenting with delayed motor milestones, calf pseudohypertrophy, and a markedly elevated creatine kinase, covering the genetic confirmation by multiplex ligation-dependent probe amplification, the glucocorticoid backbone with prednisolone or deflazacort started at the motor plateau, the cardiac and respiratory surveillance, the precision therapies, and the family counselling and the multidisciplinary plan.

paediatric neuromuscular long case5 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
A 6-year-old boy is referred to the paediatric clinic because he cannot run or climb stairs, falls often, and was kept back a year at school for slow motor development. He walked at twenty months. On examination he has a waddling, toe-walking gait with lumbar lordosis, large and firm calves, a Gowers sign that takes seven seconds, symmetrical proximal weakness worse in the legs, and reduced deep tendon reflexes. His face and extraocular movements are normal. His creatine kinase is 31,000 units per litre, his alanine aminotransferase is 220 units per litre with a normal bilirubin, and his weight is 21 kilograms.

This boy has the classic presentation of Duchenne muscular dystrophy. The delayed walking, the toe-walking gait with lumbar lordosis, the firm calf pseudohypertrophy, the Gowers sign, the proximal weakness worse in the legs, and the reduced reflexes together form a recognisable picture, and the creatine kinase of 31,000 units per litre settles the direction of the workup. The high alanine aminotransferase with a normal bilirubin is muscle-derived, because the same enzymes leak from the damaged fibre, so this is not a liver problem. [3]

Clinical findings and assessment

The key findings are the proximal weakness worse in the legs, the calf pseudohypertrophy, the Gowers sign, the reduced reflexes, and the creatine kinase of 31,000. The weakness is proximal and symmetrical, the pelvic girdle failing before the shoulder girdle, and the face and the eyes are spared, which separates a primary muscle disease from a more generalised neurological process. The firm calves are the pseudohypertrophy of fat and fibrosis that replace the necrotic fibre, and the reduced reflexes reflect the loss of the muscle. The creatine kinase, between 10,000 and 100,000, is off the scale and points to a dystrophic process. [4]

The timed function tests grade and track the disease. The time to stand from the floor, the ten-metre run, the climb of four stairs, and the six-minute walk are measured, because the trend over time reveals the motor plateau that should trigger the glucocorticoid decision and the decline that heralds the loss of ambulation. The joints are checked for the contractures of the Achilles, the hamstrings, and the iliotibial bands, the spine for the scoliosis that will come once he is in a wheelchair, and the heart for the gallop of the early cardiomyopathy. [4]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [2]Koenig M, Beggs AH, Moyer M The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet, 1989.PMID 2491009
  2. [3]Bushby K, Finkel R, Birnkrant DJ Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol, 2010.PMID 19945913
  3. [4]Birnkrant DJ, Bushby K, Bann CM Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol, 2018.PMID 29395989
  4. [5]Birnkrant DJ, Bushby K, Bann CM Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol, 2018.PMID 29395990
  5. [7]Griggs RC, Miller JP, Greenberg CR Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology, 2016.PMID 27566742
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCounsel the parents of a child with a first demyelinating event — OSCEneurology-neurodisability-and-neuromuscularNextExamining and counselling the family of a high-risk infant — OSCEneurology-neurodisability-and-neuromuscular